Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1Phase 3 1

Status

Active not recruiting 17Recruiting 16Unknown 4Terminated 4Not yet recruiting 4Completed 3Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 68Gemcitabine 64Cyclophosphamide 64toripalimab 62Paclitaxel 57pembrolizumab 55sintilimab 53Specimen Handling 53Surgical Procedures, Operative 52anlotinib 49Fluorouracil 49Magnetic Resonance Spectroscopy 48Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 38camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × isatuximab × Clear all
NCT07624513 2026-06-03

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Dana-Farber Cancer Institute

Phase 3 Not yet recruiting
720 enrolled
Plasma cell

Multiple Myeloma

NCT07601100 2026-06-01

IsaIberVD

Dana-Farber Cancer Institute

Phase 1/2 Not yet recruiting
88 enrolled
Plasma cell

Multiple Myeloma

NCT07600151 2026-05-20

CONQUISTADOR

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Not yet recruiting
220 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07334535 2026-01-13

Isa-VRD in TIE HRMM

Peking Union Medical College Hospital

Phase 4 Not yet recruiting
117 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡